Acenocoumarol in Heart Failure
Clinical studies have investigated the role of oral anticoagulants including acenocoumarol in preventing occlusion of the venous grafts in patients who have undergone a coronary artery bypass grafting (CABG). These studies have shown that the oral anticoagulants including acenocoumarol are effective in preventing reocclusion of the graft.
The implications of thromboembolism in chronic heart failure
Ambärus, V et al., Rev Med Chir Soc Med Nat Iasi. 2002 Jan-Mar;106(1):107-11.
To determine whether long-term anticoagulant therapy influences the mortality rate in congestive heart failure (CHF)
Calculation of the annual death rate of the patients with CHF class III-IV New York Heart Association (NYHA)
The annual death rate in group A was 4% and in group B was 1.2% (risk reduction 70%).
The main mechanism of death in CHF is thromboembolism and in this circumstance anticoagulant or antiplatelet therapy would be essential.